NCT00616967View on ClinicalTrials.gov

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

June 30, 2014

Study Completion Date

February 28, 2026

Conditions
Breast Cancer
Interventions
DRUG

carboplatin

Given IV

DRUG

paclitaxel albumin-stabilized nanoparticle formulation

Given IV

DRUG

vorinostat

Given orally

OTHER

placebo

Given orally

Trial Locations (5)

21401

Anne Arundel Health System, Annapolis

35249

University of Alabama Comprehensive Cancer Center, Birmingham

46202

Indiana University Purdue University of Indianapolis, Indianapolis

55905

Mayo Clinic Cancer Center, Rochester

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00616967 - Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer | Biotech Hunter | Biotech Hunter